Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…Abstract Number: 1548 • ACR Convergence 2022
Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease. But it's pathophysiology and the impact of the treatments on immune cells are poorly known. Our objectives…Abstract Number: 1305 • ACR Convergence 2022
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
Background/Purpose: Fractures in patients with systemic lupus erythematosus (SLE) are more common than age and sex matched controls. Fracture risk is traditionally assessed by dual-energy…Abstract Number: 1499 • ACR Convergence 2022
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…Abstract Number: 1544 • ACR Convergence 2022
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…Abstract Number: 1447 • ACR Convergence 2022
Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus…Abstract Number: 1508 • ACR Convergence 2022
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can't be assessed;…Abstract Number: 1555 • ACR Convergence 2022
Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study
Background/Purpose: Few studies compared the demographic, clinical, laboratory and imaging features, and outcomes of Takayasu arteritis (TAK) and large-vessel giant cell arteritis (LV-GCA). Aim of…Abstract Number: 1315 • ACR Convergence 2022
Building Stronger Bones: Optimizing Osteoporosis Screening at a Primary Care Clinic
Background/Purpose: Osteoporosis is a silent disease characterized by low bone mass and deterioration of bone quality, affecting 25% of women.1 The United States Preventive Services…Abstract Number: 1540 • ACR Convergence 2022
Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by chronic inflammation leading to damage of the vascular endothelium and excessive collagen deposition in several target organs. The…Abstract Number: 1435 • ACR Convergence 2022
Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Background/Purpose: Efficacy and safety of tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA) has demonstrated in randomized controlled trials. However, the clinical response to…Abstract Number: 1551 • ACR Convergence 2022
The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis
Background/Purpose: Takayasu Arteritis (TA) is a complex large vessel vasculitis that leads to arterial stenosis, occlusion and aneurysmal formation. Assessment of disease activity is a…Abstract Number: 1519 • ACR Convergence 2022
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Background/Purpose: Primary heart involvement in systemic sclerosis (SSc-pHI) is characterized by myocardial inflammation with resultant fibrosis that is not secondary to ischemic heart disease or…Abstract Number: 1450 • ACR Convergence 2022
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
- « Previous Page
- 1
- …
- 386
- 387
- 388
- 389
- 390
- …
- 2425
- Next Page »